close
This ad will auto close in 10 seconds

Sun Pharma shares bounce back, up nearly 2% at close

Shares of Sun Pharmaceutical Wednesday recovered nearly 2 percent to close at Rs 967.15 on BSE a day after the stock took a severe beating following Daiichi Sankyo selling its entire 9 percent stake in the company for Rs 20,025 crore.

Sun Pharma shares bounce back, up 3% on bourses

Stocks of Sun Pharmaceutical made a comeback at the bourses Wednesday, rising nearly 3 percent, a day after Japanese drugmaker Daiichi Sankyo sold its entire stake of around 9 per cent in the company for Rs 20,025 crore.

Daiichi Sankyo exits Sun Pharma; ends 7 years of tumultuous ride in India

Daiichi Sankyo exits Sun Pharma; ends 7 years of tumultuous ride in India

The company, which had forayed into the growing Indian pharmaceutical market by buying a majority stake in Ranbaxy Laboratories in 2008 for Rs 22,000 crore, sold over 21 crore shares in Sun Pharma.

Sun Pharma shares tank 11% as Daiichi completes exit

Shares of Sun Pharmaceutical on Tuesday plunged nearly 11 percent after Japan's Daiichi Sankyo announced selling its entire holding in the Indian drug major for an estimated Rs 20,420 crore.

Sun Pharma slumps most in near six years on Daiichi's share sale

Shares of Sun Pharmaceutical Industries Ltd slumped as much as 10.9 percent on Tuesday, heading towards their biggest daily fall since June 2009 after Japan`s Daiichi Sankyo Co Ltd started selling its stake in the Indian drugmaker.

Daiichi files plea in HC to vacate stay on Sun-Ranbaxy merger

Daiichi Sankyo, owner of Ranbaxy Laboratories Limited, has filed a petition in Andhra Pradesh High Court requesting it to vacate the 'status quo' order it issued earlier on Sun Pharma-Ranbaxy merger process.

Sun Pharma shares gain 7%, up 2nd day post Ranbaxy deal

The scrip ended 6.91 percent up at Rs 627.80 on the BSE. During the day, it surged 8 percent to touch Rs 634.80. Ranbaxy stock rose 4.90 percent to Rs 467.

Govt to review FDI policy in pharma sector on Monday

Government will take up on Monday the issue of tightening FDI in existing pharmaceutical companies in the wake of concerns over multinationals taking over domestic drug makers.

Daiichi Sankyo's allegations false & baseless: Malvinder Singh

Ranbaxy rebutted the allegations saying they did not misrepresent any facts or falsify any data.

Ranbaxy shares dive over 9% after Daiichi says misled over probes

Following the weakness in the stock, the market value of the company slipped by Rs 1,527 crore to Rs 16,708 crore.

Ranbaxy, Daiichi Sankyo to collaborate in Brazil to expand biz

Drug major Ranbaxy Laboratories and its Japanese parent Daiichi Sankyo on Wednesday announced synergies in Brazil to expand their business in the Latin American nation.

Ranbaxy, Daiichi Sankyo to leverage synergies in Thailand

Both the companies intend to integrate their business operations in Thailand.

Daiichi Sankyo to sell Ranbaxy's products in Venezuela

Japanese pharma major Daiichi Sankyo will start selling Ranbaxy Laboratories products in Venezuela under their hybrid business model, the two companies said on Wednesday.

Ranbaxy to sell Daiichi Sankyo's products in Italy

Drug maker Ranbaxy Laboratories and its parent firm Daiichi Sankyo Tuesday said they have entered into a partnership to distribute the Japanese firm's products in Italy.

Ranbaxy Daiichi Sankyo to spend 200 mn yen on mobile clinics

Drug major Ranbaxy on Wednesday said it will spend nearly 200 million yen (over Rs 10 crore) along with parent company Daiichi Sankyo over the next five years to sponsor mobile healthcare field clinics in India, Cameroon and Tanzania.

Ranbaxy buyout boosts Daiichi profit 10-fold

Daiichi Sankyo posted an April-June recurring profit of 70.1 billion yen (USD 808 million), up from 7.2 billion yen a year earlier.

Ranbaxy to launch Daiichi Sankyo`s drug in Africa

The country`s largest drug maker by sales, Ranbaxy Laboratories, today said it would launch Olmesartan Medoxomil, an anti-hypertensive drug from parent company Daiichi Sankyo`s portfolio, in six African countries.

Ranbaxy to launch Daiichi Sankyo`s drug in Africa

Ranbaxy Laboratories will launch Olmesartan Medoxomil, an anti-hypertensive drug from parent company Daiichi Sankyo`s portfolio, in six African countries.

Daiichi Sankyo to launch Ranbaxy`s drugs in Japan soon

Daiichi Sankyo, which has a
majority stake in Ranbaxy Laboratories, today said it is going
to launch some of Ranbaxy`s generic medicine in the Japanese
market soon.

Daiichi Sankyo moves SC against SAT order on share price

Leading Japanese drug-maker Daiichi Sankyo has challenged the Securities Appellate Tribunal (SAT) judgement that asked it to make an open offer to shareholders of Zenotech Labs at Rs 160 per share.